Alerts
4850 total results. Page 1 of 194.
Effective April 17, the US Patent and Trademark Office (USPTO) suspended the expedited examination process for design patent applications under 37 CFR 1.155, commonly referred to as the “Rocket Docket.”
On July 30, the US Food and Drug Administration (FDA) released its Expanded Decision Tree (EDT), a new science-based tool designed to screen and evaluate the safety or toxicity of chemicals in food.
A South Carolina state trial court recently dismissed a climate tort case filed by the City of Charleston seeking to hold major energy companies liable for harms allegedly caused by climate change. This ended a case that had bounced between state and federal courts for much of the last decade.
The US Patent and Trademark Office (USPTO) has issued new guidance to clarify and improve the evaluation of patent eligibility for artificial intelligence (AI) and machine learning (ML) inventions in order to foster innovation and patenting of these cutting-edge technologies.
On August 6, the US Food and Drug Administration (FDA) issued an update regarding the use of per- and polyfluoroalkyl substances (PFAS), specifically fluoropolymers such as polytetrafluoroethylene (PTFE), in medical devices. The FDA concluded that, based on current scientific evidence, there is no reason to restrict the continued use of fluoropolymers in medical devices.
On July 31, the US Patent and Trademark Office (USPTO) issued a new memorandum announcing that it will begin enforcing 37 C.F.R. § 42.104(b)(4) that requires petitioners in inter partes review (IPR) proceeding to “specify where each element of the claim is found in the prior art patents or printed publications relied upon.”
On July 4, President Donald Trump signed into law P.L. 119-21, the “One Big Beautiful Bill Act” (OBBBA), which, among other notable changes to the US tax system, rolls back several renewable energy incentives enacted under the Inflation Reduction Act of 2022 (IRA) and creates new restrictions on renewable energy incentives for taxpayers with certain foreign entity connections, which are detailed below.
The court held that the statute of limitations began to run from the date when a former employee produced confidential company financial during discovery in an unrelated matter, and not from the earlier date when the former employee had copied and taken the files, because defendants had not failed to exercise reasonable diligence to uncover the alleged misappropriation.
On July 4, President Trump signed into law the “One Big Beautiful Bill Act (OBBBA),” more formally known as “H.R.1 – An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14.”
Headlines that Matter for Companies and Executives in Regulated Industries
On July 22, the US Senate passed the Maintaining American Superiority by Improving Export Control Transparency Act (the Bill), sending it to President Trump for his signature.
The Trump Administration is moving aggressively to prevent foreign adversaries’ ownership of US agricultural land.
On July 29, the Attorney General (AG) of the United States issued a memorandum entitled “Guidance For Recipients of Federal Funding Regarding Unlawful Discrimination” (hereinafter “Guidance”). This alert provides a review of the guidance and recommendations for consideration.
The Committee on Foreign Investment in the United States (CFIUS) is back in the spotlight.
This fall, Congress is poised to consider and develop legislation differing in type and scope — from funding measures to reconciliation proposals.
The District of Columbia’s Access to Justice (ATJ) Initiative is the primary local mechanism for public funding of civil legal services to low- and moderate-income DC residents.
On July 29, the US Environmental Protection Agency (EPA) announced a proposal to rescind its 2009 Endangerment Finding.
An association’s board often confronts difficult decisions. One that is particularly challenging is whether and how to remove a sitting director.
On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical manufacturers can honor the 340B price.
After weeks of anticipation and a flurry of news from Washington, DC, the White House has issued a long-awaited executive order (EO) that resets the landscape for US reciprocal tariffs and related trade measures.
The climate debate has whipsawed in recent years. Businesses frequently have been caught in the middle, with stakeholders including government regulators, activist investors, consumers, non-governmental organizations, and community groups all pursuing different agendas.
Headlines that Matter for Companies and Executives in Regulated Industries
On July 21, the US Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN) announced a two-year postponement of the Anti-Money Laundering (AML)/Countering the Financing of Terrorism (CFT) Program and Suspicious Activity Report filing requirements for registered investment advisers (IAs) and exempt reporting advisers.
In this episode of Five Questions, Five Answers, host Birgit Matthiesen welcomes AFS attorney James Kim to explore the current state of US tariffs and their impact on importers and various industries, with a special focus on the electric vehicle sector.
Immigration enforcement actions are no longer a theoretical concern for health care facilities — they are happening now.